Related Experiment Video
Updated: Jul 18, 2026

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity
Published on: May 12, 2020
Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia
Constance J Glover1, Alfred A Rabow, Yasemin G Isgor
1Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, MD 21702, USA. cglover@mail.ncifcrf.gov
Abstract:
Mitochondria are principal mediators of apoptosis and thus can be considered molecular targets for new chemotherapeutic agents in the treatment of cancer. Inhibitors of mitochondrial complex I of the electron transport chain have been shown to induce apoptosis and exhibit antitumor activity. In an effort to find novel complex I inhibitors which exhibited anticancer activity in the NCI's tumor cell line screen, we examined organized tumor cytotoxicity screening data available as SOM (self-organized maps) (http://www.spheroid.ncifcrf.gov) at the developmental therapeutics program (DTP) of the National Cancer Institute (NCI). Our analysis focused on an SOM cluster comprised of compounds which included a number of known mitochondrial complex I (NADH:CoQ oxidoreductase) inhibitors. From these clusters 10 compounds whose mechanism of action was unknown were tested for inhibition of complex I activity in bovine heart sub-mitochondrial particles (SMP) resulting in the discovery that 5 of the 10 compounds demonstrated significant inhibition with IC50's in the nM range for three of the five. Examination of screening profiles of the five inhibitors toward the NCI's tumor cell lines revealed that they were cytotoxic to the leukemia subpanel (particularly K562 cells). Oxygen consumption experiments with permeabilized K562 cells revealed that the five most active compounds inhibited complex I activity in these cells in the same rank order and similar potency as determined with bovine heart SMP. Our findings thus fortify the appeal of mitochondrial complex I as a possible anticancer molecular target and provide a data mining strategy for selecting candidate inhibitors for further testing.
Insights
Researchers identified novel mitochondrial complex I inhibitors with anticancer potential. These compounds show significant cytotoxicity against leukemia cells, particularly K562, reinforcing mitochondria as a key cancer target.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Mitochondria play a crucial role in apoptosis, making them attractive targets for cancer chemotherapy.
- Inhibitors of mitochondrial complex I (NADH:CoQ oxidoreductase) have demonstrated antitumor activity and the ability to induce apoptosis.
Purpose of the Study:
- To identify novel mitochondrial complex I inhibitors with anticancer activity.
- To utilize National Cancer Institute (NCI) data mining strategies to find potential chemotherapeutic agents.
Main Methods:
- Analysis of self-organized maps (SOM) data from the NCI's Developmental Therapeutics Program (DTP).
- Screening of 10 compounds with unknown mechanisms for complex I inhibition using bovine heart sub-mitochondrial particles (SMP).
- Cytotoxicity assessment of identified inhibitors against NCI tumor cell lines, focusing on leukemia subpanels.
Main Results:
- Five out of ten tested compounds significantly inhibited mitochondrial complex I activity, with three showing nanomolar IC50 values.
- The identified inhibitors demonstrated potent cytotoxicity against leukemia cell lines, especially K562.
- Inhibition of complex I activity in K562 cells correlated with results from bovine heart SMP experiments.
Conclusions:
- Mitochondrial complex I is a viable molecular target for anticancer drug development.
- The data mining approach using SOM clusters is effective for identifying promising complex I inhibitors.
- Further investigation of these compounds is warranted for their potential as novel chemotherapeutic agents.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
